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Abstract
Accurate models of clinical actions and their impacts on disease progres-
sion are critical for estimating personalized optimal dynamic treatment regimes
(DTRs) in medical/health research, especially in managing chronic conditions.
Traditional statistical methods for DTRs usually focus on estimating the opti-
mal treatment or dosage at each given medical intervention, but overlook the
important question of “when this intervention should happen.” We fill this gap
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by building a generative model for a sequence of medical interventions—which
are discrete events in continuous time—with a marked temporal point process
(MTPP) where the mark is the assigned treatment or dosage. This clinical ac-
tion model is then embedded into a Bayesian joint framework where the other
components model clinical observations including longitudinal medical measure-
ments and time-to-event data. Moreover, we propose a policy gradient method
to learn the personalized optimal clinical decision that maximizes patient sur-
vival by interacting the MTPP with the model on clinical observations while
accounting for uncertainties in clinical observations. A signature application of
the proposed approach is to schedule follow-up visitations and assign a dosage
at each visitation for patients after kidney transplantation. We evaluate our ap-
proach with comparison to alternative methods on both simulated and real-world
datasets. In our experiments, the personalized decisions made by our method
turn out to be clinically useful: they are interpretable and successfully help im-
prove patient survival. The R package doct (short for “Decisions Optimized in
Continuous Time”) implementing the proposed model and algorithm is available
at https://github.com/YanxunXu/doct.
Keywords: Bayesian joint model, dynamic treatment regimes, electronic health records,
marked temporal point process, policy gradient.
1 Introduction
In biomedical applications involving long-term personalized care of patients with
chronic health conditions (e.g., diabetes, HIV infections, and chronic kidney diseases),
treatments often include a sequence of decision making and must be adaptive to the
uniquely evolving disease progression of each patient. Such scenarios are called dynamic
treatment regimes (DTRs). Patients with chronic diseases are usually required to
2
follow up with their physicians from time to time and their clinical data are recorded
longitudinally. Based on these clinical observations, physicians make clinical decisions
such as scheduling follow-up visitations and prescribing the right dosages to optimize
patient outcomes given a patient’s individual characteristics and treatment history at
each clinic visitation. This paper develops a Bayesian joint framework consisting of a
generative probabilistic model for clinical decisions with timing and a model for clinical
observations (e.g., longitudinal clinical measurements and time-to-event data): these
two models share certain structures and parameters in order to capture the mutual
influence between the clinical observations and decisions. Furthermore, we propose
an optimization method that allows the decision model, by interacting with the other
parts of the joint framework, to learn to make the personalized optimal clinical decision
at the right time. Such a joint model and the proposed optimization method will be
useful in many biomedical applications. We elaborate on one signature application in
section 1.1, explain why existing methods won’t work well on it in section 1.2, and
then give an overview of our method and its technical novelty in section 1.3.
1.1 A signature application
A signature medical application of the proposed method would be the kidney
transplantation—the most common type of organ transplantation and the primary
therapy for patients with end-stage kidney diseases (Arshad et al., 2019). Compared
to dialysis, kidney transplantation improves patients’ long-term survival and quality of
life but with a lower healthcare cost (Jarl et al., 2018). Despite significant advances,
a number of complications after surgery still represent important causes of morbid-
ity and mortality for kidney transplant recipients, such as infection, stroke, and graft
failure (Lamb and Lodhi, 2011; Bicalho et al., 2019). To prevent graft rejection, pa-
tients are usually hospitalized for a few days initially to monitor signs of complications,
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then required to have frequent checkups at an outpatient center after being released. At
each visitation, they are administered immunosuppressive drugs, such as tacrolimus, to
keep their immune systems from attacking and rejecting the new kidney (Kasiske et al.,
2010). One crucial medical decision is to schedule the patients’ post-transplantation
follow-up visitations. While follow-up visitation frequency varies from 0-12 months
(Israni et al., 2014), patients with stable kidney function usually have less frequent
follow-ups compared to non-stable patients. Another medical decision is to determine
the right dosage of tacrolimus at each follow-up visitation since a dosage that is either
very high or too low may cause serious adverse events. Higher tacrolimus levels have
been reported to associate with adverse effects such as neurotoxicity, nephrotoxicity,
and cancers (Naesens et al., 2009); while lower tacrolimus levels are associated with
an increased likelihood of graft rejection (Staatz et al., 2001). Therefore, optimizing
personalized follow-up schedules and prescribing the right dosage of tacrolimus tailored
to each patient at each visitation (i.e., precision medicine) are critical and can have a
significant impact on patients’ survival.
Large-scale kidney transplantation databases, such as French computerized and
validated data in transplantation (DIVAT), provide us opportunities and challenges
to determine personalized optimal follow-up schedules and tacrolimus dosages. DI-
VAT is a database storing medical records for kidney transplantation in several French
hospitals (e.g., Nantes, Paris Necker). Data are collected from the date of transplan-
tation until the graft failure, defined as either returning to dialysis or death with a
functioning graft. At each scheduled follow-up visitation, patients’ creatinine levels,
an important biomarker for measuring kidney function, are collected longitudinally to
determine the next follow-up time and assign dosages by physicians. For example, Fig-
ure 1 presents one randomly selected patient’s longitudinal creatinine levels, tacrolimus
dosages versus his/her follow-up visitations from DIVAT. In the first several visitations
4
after kidney transplantation, this patient’s creatinine levels were high, indicating the
kidney was not functioning well, therefore, the physician scheduled a high frequency of
follow ups and prescribed high dosages of tacrolimus. As time went by, this patient’s
kidney function became stable indicated by slowly decreasing creatinine levels, then
the prescribed tacrolimus dosages were also slowly decreasing accompanied with a de-
creasing frequency of visitations. For patients with kidney transplantation, a major
clinical outcome of interest is the graft survival time, defined as the time between the
transplantation and the first graft failure. Follow-up schedules and tacrolimus dosages
should be made for the sake of maximizing patients’ graft survival time.
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Figure 1: Example data for one patient’s creatinine and tacrolimus levels on a log scale
over time. The points represent actual visitations.
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1.2 Why not use existing methods?
Although many statistical and machine learning DTR methods have been devel-
oped to optimize sequential clinical decisions (Murphy et al., 2003; Chakraborty, 2013;
Laber et al., 2014; Xu et al., 2016; Luckett et al., 2019), they don’t model, and thus
can’t optimize, the timing of clinical decisions. Most DTR methods regard treatment
schedules as known a priori and only learn to adjust other clinical decisions. For ex-
ample, Xu et al. (2016) developed a Bayesian nonparametric approach building upon
a dependent Dirichlet process and a Gaussian process to determine the optimal treat-
ment regimen containing a front-line chemotherapy and a salvage treatment for acute
myelogenous leukemia patients. However, the timing of the salvage treatment was pre-
defined as the time when patients became resistant to the front-line chemotherapy or
achieved complete remission first then relapsed. Clifton and Laber (2020) reviewed
the use of Q-learning, a general class of reinforcement learning methods, in estimating
optimal treatment regimens taking the timing of the treatment as given. Guan et al.
(2019) attempted to optimize treatment schedules: they developed a Bayesian non-
parametric method that learns to recommend a regular recall time for patients with
periodontal diseases. However, their method only picks the recall time out of a few
pre-defined choices (e.g., 3 months, 6 months, and 9 months) and thus is not applicable
to complicated scenarios like the one introduced in section 1.1: at each visitation after
kidney transplantation, the next visitation time has to be carefully scheduled given the
current clinical measurement in order to maximize the patient’s health outcome. For
instance, when patients’ kidney function is relatively stable, they should be instructed
to wait longer until the next visitation compared to those who are less stable.
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1.3 Why use our method?
To the best of our knowledge, the proposed approach is the first general methodol-
ogy for estimating personalized optimal clinical decisions with timing. The method is
cutting-edge because (1) we build a generative probabilistic model that properly han-
dles clinical decisions with timing; (2) we embed this decision model into a Bayesian
joint framework that also models clinical observations; (3) we train it using a policy
gradient method to generate personalized treatment schedules alongside other clinical
decisions that would optimize patients’ health outcomes.
Our decision model is a marked temporal point process (MTPP) (Aalen et al., 2008),
which is a natural tool to model discrete events in continuous time. It has been widely
applied and become increasingly popular in various domains, including social science
(Butts and Marcum, 2017), medical analytics (Liu et al., 2018), finance (Hawkes, 2018),
and stochastic optimal control (Tabibian et al., 2019). In our example application of
section 1.1, each follow-up visitation is an event: the visitation time is assumed to be
stochastically scheduled according to the probability distribution characterized by the
proposed MTPP; and the assigned tacrolimus dosage, when the visitation happens, is
treated as the corresponding “mark.”
The proposed MTPP for clinical decisions is then embedded into a Bayesian joint
framework where it shares certain structures and parameters with the other compo-
nents modeling clinical observations, including longitudinal creatinine measurements
and patient survival in the example application of section 1.1. Such design allows our
model to capture the complicated mutual influence between clinical observations (e.g.,
creatinine levels) and decisions (e.g., treatment schedules and tacrolimus dosages).
Next, we fit the proposed Bayesian joint model on clinical observations and deci-
sions to the data, and then let the decision model interact with the observation model
in an optimization procedure. This technique is known as “reinforcement learning”
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(Sutton and Barto, 2018): the decision model (also called the “policy”) is reinforced,
by the feedback from the observation model (also called the “environment”), to give
personalized optimal treatment schedules and dosages that would improve the expected
health outcome for each patient. The Bayesian nature of our joint framework allows the
learning to account for parameter uncertainties in the observation model. Figure 2 illus-
trates the proposed Bayesian joint framework and how its components interact. The R
package doct (short for “Decisions Optimized in Continuous Time”) implementing the
proposed model and algorithm is available at https://github.com/YanxunXu/doct.
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Figure 2: Illustration of the proposed method.
The rest of the paper is organized as follows. In section 2, we present the proposed
Bayesian joint model consisting of the decision model (for visitation schedules and
dosages) and the observation model (for clinical longitudinal measurements and patient
survival). In section 3, we elaborate on our optimization procedure for the decision
model. We evaluate the proposed method through simulation studies in section 4
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and applying it to the DIVAT kidney transplantation dataset in section 5. Lastly, we
conclude the paper with a discussion in section 6.
2 A Bayesian Joint Model
In this section, we describe the proposed Bayesian joint framework that models
both clinical decisions and observations. In section 2.1, we introduce the clinical deci-
sion model for follow-up visitation schedules and dosages; in section 2.2, we introduce
the clinical observation model for longitudinal measurements and time-to-event data,
which are linked to the decision model through parameter sharing. To facilitate our
presentation and readers’ understanding, we will use the kidney transplantation ex-
ample and the DIVAT data to illustrate the model. However, the proposed method is
applicable to general medical settings since the patterns that the method can capture
are not tied to this particular application.
2.1 Modeling clinical decisions
Modeling event data with marker information is important to learn the latent mech-
anisms that govern the observed stochastic event patterns over time in many domains,
such as social science (Butts and Marcum, 2017) and medical analytics (Liu et al.,
2018). Marked temporal point processes (Aalen et al., 2008) are a general framework
for modeling such event data. Formally, a marked temporal point process is a random
process, the realization of which consists of a sequence of events localized in time, i.e.,
H = {(t0, d0), (t1, d1), . . . , (tJ , dJ)} with the occurrence time of event j being tj ∈ R+
and dj is the associated mark. In our application, tj represents the time when a pa-
tient visits an outpatient center and dj represents the tacrolimus dosage assigned by
the physician. The first event is defined as the day of transplantation at t0 = 0 with
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an initial dose d0.
Denote the event history up to time t to be Ht = {(tj, dj) ∈ H | tj < t}. Under
MTPP, the instantaneous rate of the event is characterized by a conditional intensity
function λ(t), namely λ(t) = limdt→0
Pr{event happens in [t,t+dt)|Ht}
dt
. Common forms of the
conditional intensity function λ(t) include Poisson process (Zhu and Li, 2018), Gamma
process (Shibue and Komaki, 2020), Hawkes process (Hawkes, 1971). However, these
common models cannot capture complicated patterns in many medical applications.
For instance, as shown in Figure 3(a) that plots the empirical intensity of the amount
of time between visitations for different ranges of creatinine levels in the DIVAT data,
the elapsed time between follow-up visitations is correlated with the creatinine level.
Also, the empirical intensities of visitations are observed to quickly rise to a peak and
then fall down accompanied by moderate oscillations. Such complication is beyond
the capacity of the Poisson process that assumes a constant intensity and the Gamma
process whose intensity function is monotonic. The Hawkes process assumes that the
past events always elevate the intensities of future events and this “self-exciting” effect
is additive—it is also apparently not the dynamics that the visitations in the DIVAT
data actually follow. Its neural extensions (Du et al., 2016; Mei and Eisner, 2017) are
flexible enough to fit complex data but unable to explicitly incorporate human expert
knowledge.
We propose a flexible conditional intensity function that also incorporates human in-
tuition: it takes longitudinal clinical measurements into account and captures patients’
heterogeneity. Denote yi,j to be the longitudinal clinical measurement of interest: in our
kidney transplantation application, it is the logarithm of the creatinine level (µmol/l),
for patient i at the j-th follow-up visitation occurring at time ti,j (days), i = 1, . . . , I,
j = 0, . . . , Ji. Note here ti,0 = 0 denotes the transplantation date of patient i, and yi,0
denotes the initial creatinine level. Our conditional intensity function makes use of a
10
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Figure 3: Panel (a) shows the empirical intensity plot for the amount of time (in days)
between follow-up visitations. Panel (b) plots an example of how creatinine levels and
model parameters affect the visitation intensity, where k = 2, βα = (10,−1.8)T , µ =
−4.4, ν1 = 1.5, and ν2 = 1.
Gamma density function as follows:
λi(t) = exp(µ)︸ ︷︷ ︸
Baseline Intensity
+ αi,j (t− ti,j)κ−1e−γ(t−ti,j) γ
κ
Γ(κ)︸ ︷︷ ︸
Gamma density
for t ∈ (ti,j, ti,j+1], (2.1)
where αi,j > 0, γ > 0, κ ≥ 1. The parameter αi,j is patient-specific so that our intensity
function λi is personalized. We set κ = exp(ν2) + 1 > 1 so that the intensity rises to
a “global peak” and then decreases: it would eventually approach to the “baseline
level” exp(µ) unless the next visitation happens and sets up a new intensity curve.
For easy interpretation, we parameterize γ as γ = exp(ν2 − ν1) such that the “peak
time” (i.e., when the peak of the intensity function occurs) can be easily computed
as κ−1
γ
= exp(ν1). Moreover, since the intensity level is often correlated with the
clinical measurement (e.g., as in Figure 3(a), a higher creatinine level implies a higher
intensity), we condition the parameter αi,j, which controls the peak intensity for patient
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i between time ti,j and ti,j+1, on the clinical measurement taken at the j-th visitation:
αi,j =
ξ
1 + exp((1, yi,j)βα)
.
This design reflects the human intuition that the time of “next visit” is usually deter-
mined based on the clinical measurement of “this visit.” Note that our design allows
incorporating other covariates (i.e., measurements) by simply augmenting them to the
vector (1, yi,j). Figure 3(b) shows how the visitation intensity under our model is af-
fected by the most recent creatinine level yi,j (and thus the magnitude parameter αi,j)
given a specific set of parameter values.
Next, we model the dosage di,j at the j-th visitation of patient i as the “mark” of
the visitation event: in the kidney transplantation application, it is the logarithm of
the tacrolimus level (ng/ml). Generally speaking, the physician would assign a dosage
based on the patient’s current clinical measurement yi,j and potential risk factors xi.
We assume the following dosage model reflecting this knowledge:
di,j = (1, yi,j,xi)βd + d, (2.2)
where d ∼ Normal(0, σ2d). In the kidney transplantation application, xi includes
baseline risk factors that would affect graft failure such as the patient’s age when
receiving the transplantation and the donor type. Thus, the probability of the i-th
patient’s sequence of visitations and assigned dosages ei,Ti = {(ti,0, di,0), . . . , (ti,Ji , di,Ji)}
up to time Ti can be written as
p(ei,Ti | yi,xi,βv,βd, σ2d)
= exp
(
−
∫ Ti
0
λi(t | yi,βv)dt
)
︸ ︷︷ ︸
Prob. of no visits at t∈[0,Ti]\{ti,j}Jij=1
Ji∏
j=0
p(di,j | yi,j,xi,βd, σ2d)︸ ︷︷ ︸
Prob. of dosage
Ji∏
j=1
(2.1)︷ ︸︸ ︷
λi(ti,j | yi,j−1,βv)︸ ︷︷ ︸
Prob. of a visit at ti,j
,
(2.3)
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where yi = (yi,0, . . . , yi,Ji), βv = {µ, ν1, ν2, ξ,βα}.
2.2 Modeling clinical observations
In this section, we introduce the clinical observation model of the Bayesian joint
framework that handles longitudinal measurements and time-to-event data. In the
kidney transplantation application, the longitudinal measurement is the creatinine level
and the time-to-event data is the graft survival time. We will also show how it is linked
to the MTPP model proposed in section 2.1 by carefully designing parameter sharing
in order to capture the mutual influence between clinical observations and decisions.
Shortly in section 3, we will leverage this joint framework to optimize clinical decisions
with the goal of maximizing patients’ survival.
Our clinical observation model is composed of two submodels—a linear mixed effects
model for longitudinal clinical measurements (e.g., creatinine levels) and a time-to-
event model for patient survival (e.g., graft survival time after kidney transplantation).
The two submodels are then connected by sharing random effects (Rizopoulos et al.,
2014). Recall that yi,j = yi(ti,j) denotes the longitudinal measurement value for patient
i at j-th follow-up visitation at time ti,j, i = 1, . . . , I, j = 0, . . . , Ji. Let y
∗
i (t) be the
underlying true but unobserved longitudinal process at time t ≥ 0. We assume
yi(t) = y
∗
i (t) + l = zi(t)βl + ri(t)bi + l, (2.4)
where l ∼ Normal(0, σ2l ) and bi ∼ Normal(0,Σb). The covariate vectors zi(t) and
ri(t) are associated with fixed and random effects respectively:
zi(t) = (1, di(t),xi, t, t
2) and ri(t) = (1, di(t), t),
where di(t) at time t is the dosage assigned by the physician at the most recent visi-
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tation, i.e., di(t) = di,j for t ∈ (ti,j, ti,j+1]. The temporal dependence of z and r on the
dosage d captures the drug effect on the longitudinal measurements of interest: in the
kidney transplantation application, it is supposed to capture the suppressive effect of
tacrolimus on the creatinine level. Denote di = (di,0, . . . , di,Ji), the probability of the
observed sequence of creatinine measurements yi is
p(yi | di,xi,βl, σ2l , bi) =
Ji∏
j=1
p(yi,j | ti,j, di,j−1,xi,βl, σ2l , bi). (2.5)
Next, we construct the time-to-event submodel depending on the underlying true
longitudinal trajectory y∗i (t) and the MTPP that models clinical decisions. We consider
a Cox proportional hazards model with a Weibull baseline hazard as follows:
hi(t) = exp
(
− ( βs1y∗i (t)︸ ︷︷ ︸
longitudinal effect
+ βs2di(t) + βs3Toxi(t)︸ ︷︷ ︸
dosage effect
+ βs4αi(t)︸ ︷︷ ︸
visitation effect
+h0)
)
sts−1,
(2.6)
where s is the shape parameter of the Weibull baseline hazard. The dependence on
y∗i (t) reflects the domain knowledge that the survival event is usually associated with
the underlying health condition reflected by longitudinal measurements. The dosage
effect term in equation (2.6) measures the overall drug effect on the patient: βs2di(t)
is the “instantaneous” effect while βs3Toxi(t) is the “accumulated” effect:
Toxi(t) =
∫ t
0
di(τ)ηtox exp(−(t− τ)/ηtox)dτ,
where the parameter ηtox controls the rate of the exponential weighting for the past
dosages. In practice, the instantaneous effect is usually beneficial (e.g., tacrolimus
reduces the likelihood of graft rejection or death) while the accumulated effect is often
toxic (and that is why we name it Tox): e.g., a prolonged high dosage of tacrolimus
might have adverse effects on kidneys, central nervous system, and gastrointestinal
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tract, thereby worsening a patient’s survival (Randhawa et al., 1997). We also link the
survival submodel with the visitation model by defining αi(t) = αi,j for t ∈ (ti,j, ti,j+1]
since a high visitation intensity (i.e., larger αi,j) typically implies a higher risk, e.g.,
graft failure and thus shorter expected survival time.
Let Ti and Ci denote the survival and censoring times for patient i, respectively.
We observe only T˜i = min(Ti, Ci) and the censoring indicator δi = 1(Ti ≤ Ci). Denote
fi(t) and Si(t) to be the corresponding density and survival functions of the hazard
function (2.6): Si(t) = exp(−
∫ t
0
hi(u)du), fi(t) = hi(t)Si(t). We can write the survival
likelihood for patient i as
p(T˜i, δi | yi,xi, ei,T˜i ,βl, bi,βs) = fi(T˜i | yi,xi, ei,T˜i ,βl, bi,βs)δi
×Si(T˜i | yi,xi, ei,T˜i ,βl, bi,βs)1−δi , (2.7)
where βs = {s, βs1, βs2, βs3, βs4, h0, ηtox,βα, ξ}.
In summary, we propose a joint model consisting of an MTPP for clinical decisions
including follow-up visitation schedules and dosages, a linear mixed effects model for
longitudinal clinical measurements, and a time-to-event model for the patient survival;
they are inter-connected by sharing structures and parameters. The joint probability
of the clinical observations and decisions can then factor as
I∏
i=1
p(yi, ei,T˜i , T˜i, δi | xi,βl,βd,βv,βs, bi, σ2l , σ2d)
∝
I∏
i=1
(
p(ei,T˜i | yi,xi,βv,βd, σ2d)︸ ︷︷ ︸
(2.3)
p(yi | di,xi,βl, σ2l , bi)︸ ︷︷ ︸
(2.5)
p(T˜i, δi | yi,xi, ei,T˜i ,βl, bi,βs)︸ ︷︷ ︸
(2.7)
)
.
(2.8)
We complete the model by imposing the following priors: βd ∼ Normal(βd0,Σβd),
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σ2d ∼ InverseGamma(pid1, pid2), βl ∼ Normal(βl0,Σβl), σ2l ∼ InverseGamma(pil1, pil2)
for conjugacy. We assume a flat prior for Σb. When conjugacy is unattainable for the
visitation and survival parameters, we assume βs1, βs2, βs3, βs4, h0 ∼ Normal(βs0, σ2s0),
ηtox ∼ Gamma(pis1, pis2), s ∼ Gamma(pis3, pis4), µ, ν1, ν2 ∼ Normal(βv0, σ2v0), βα ∼
Normal(βα0,Σβα), and ξ ∼ Gamma(piv1, piv2). We carry out posterior inference using
the Markov chain Monte Carlo (MCMC) sampler. The details are included in the
Supplementary Material Section A.
3 Optimize Personalized Clinical Decision
Our goal is to optimize personalized clinical decision including scheduling a pa-
tient’ follow-up visitations and prescribing dosages to maximize the patient’ health
outcome, e.g., the graft survival time in the kidney transplantation application. In
this section, we first formally define our optimization problem, then propose a policy
gradient method using stochastic gradient descent (SGD) (Ruder, 2016) to optimize
personalized clinical decision.
Let θ = (ν1, ν2, µ,βd, σ
2
d) denote the set of “policy” parameters related to clinical
decisions, i.e., the parameters that only appear in the conditional intensity function
(2.1) and the mark distribution (2.2), which control patients’ follow-up schedules and
dosages at follow-up visitations. Let φ = (βs, bi,βl, σ
2
l ) denote the set of “observation”
parameters, i.e., all other parameters in the joint model (2.8). Our goal is to find, for
each patient i, the optimal “policy”, i.e., the intensity function and mark distribution
with the optimal parameter θ˜i that maximizes the patient’s expected survival time.
Note here we have index i for θ˜i since the optimal parameters may be different for
patients with different baseline covariates, yielding personalized optimal clinical deci-
sion. We borrow the term “policy” from reinforcement learning (RL) since the setting
is similar: in RL, the “policy” refers to the distribution from which an intelligent agent
16
samples its actions and that distribution is optimized to achieve the highest expected
reward (Kaelbling et al., 1996; Sutton and Barto, 2018). In the kidney transplanta-
tion application, we define a personalized reward function Ri as the log-scaled median
survival time to optimize patients’ survival: Ri = log(T̂i), where Si(T̂i) = 0.5. If de-
sired, other reward functions can be considered. For example, if a physician or patient
would like to take into consideration the healthcare cost per visit, we could penalize
the number of visitations in the reward function, e.g., Ri = log(T̂i) + η0Ci, where η0 is
a tuning parameter and Ci is the number of visitations.
Without loss of generality, we assume that each patient i receives an arbitrary
stochastic reward that is a function of the survival time: Ri(Ti), which depends on the
MTPP ei,Ti for clinical decisions, the longitudinal process yi, and the survival time Ti.
Formally, denote the expected reward for any patient i to be
Gi(θ) =
∫
E(yi,Ti,ei,Ti )∼p(yi,Ti,ei,Ti |θ,φ)[Ri(Ti)]p(φ | D)dφ, (3.1)
where p(yi, Ti, ei,Ti | θ,φ) is the joint distribution of (yi, Ti, ei,Ti) in (2.8), D denotes
the observed data, and p(φ | D) is the posterior distribution of φ. The expectation is
taken over all possible realizations of (yi, Ti, ei,Ti). We aim to find the optimal clinical
decision, represented by θ˜i, to maximize the expected reward Gi(θ) for patient i after
integrating out the uncertainty in the longitudinal process and the survival distribution:
maximizep(ei,Ti |θ)Gi(θ),
where p(ei,Ti | θ) is the probability density of the MTPP.
To find the optimal clinical decision parameter θ˜i for patient i, we use stochastic gra-
dient descent (SGD) (Robbins and Monro, 1951), i.e., θi,m+1 = θi,m+si,m∇θGi(θ) |θ=θi,m ,
which requires computing the gradient of the expected reward: ∇θGi(θ). As the ex-
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pectation is taken over realizations of the joint distribution p(yi, Ti, ei,Ti | θ,φ), it
is intractable to directly compute ∇θGi(θ). Fortunately, we can indirectly compute
this gradient by taking the expectation of the reward-weighted gradient of log-policy.
Precisely,
Proposition 1. For the i-th patient with baseline covariates xi, given a joint distri-
bution p(yi, Ti, ei,Ti | θ,φ), the gradient of the expected reward Gi(θ) with respect to θ
is:
∇θGi(θ) =
∫
E(yi,Ti,ei,Ti )∼p(yi,Ti,ei,Ti |θ,φ)[Ri(Ti)∇θ log p(ei,Ti | yi,xi,φ,θ)]p(φ | D)dφ,
where p(ei,Ti | yi,xi,φ,θ) is the probability of the i-th patient’s sequence of visitations
and assigned dosages in (2.3).
We leave the detailed proof of Proposition 1 to Supplementary Section B.
According to Proposition 1, in order to compute ∇θGi(θ), we first need to be
able to sample yi, Ti, ei,Ti from p(yi, Ti, ei,Ti | θ,φ) and calculate Ri(Ti) from the
generated samples. We sample the j-th follow-up visitation time ti,j and the survival
time Ti using an inverse transform sampling method: first computing the cumulative
distribution function (CDF) of the distribution, sampling a random number U from
Uniform(0, 1), and then inverting the CDF function at U to yield the visitation/survival
time (Giesecke et al., 2011). If the j-th visitation time occurs before the survival time,
i.e., ti,j < Ti, we sample yi,j and di,j from their respective distributions and continue to
sample the (j+1)-th visitation time and the survival time. We iteratively sample follow-
up visitation times, survival times, longitudinal measurements, and dosages until the
sampled survival event occurs before the next visitation time. After obtaining samples
of yi, Ti, ei,Ti , we can easily compute Ri(Ti). We describe the sampling process for a
general Ri in Algorithm 1. The algorithm details of sampling yi, Ti, ei,Ti , Ri(Ti) for the
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reward being the log median survival time are provided in Supplementary Section C.
Algorithm 1 Sampling yi, Ti, ei,Ti from the joint model and computing Ri(Ti)
Using the superscript s to denote the simulated data, esi,T si ={(tsi,0, dsi,0), . . . , (tsi,Jsi , dsi,Jsi )} and ysi = (ysi (tsi,1), . . . , ysi (tsi,Jsi )) denote the simulated
follow-up schedules, dosages, and longitudinal data over Jsi visits until the survival
time, T si .
Input: θ, φ, xi, yi,0
Output: ysi , T
s
i , e
s
i,T si
, Ri(T
s
i )
1: Initialize j ← 1, continue ← true
2: tsi,0 ← 0
3: ysi (0)← yi,0
4: dsi,0 ← Normal((1, ysi (0),xi)βd, σ2d)
5: while continue do
6: Uv ← Uniform(0, 1)
7: Solve for tsi,j : 1− exp(−
∫ tsi,j
tsi,j−1
λi(x)dx) = Uv
8: Us ← Uniform(0, 1)
9: Solve for T si : 1− exp(−
∫ T si
tsi,j−1
hi(x)dx) = Us
10: if T si > t
s
i,j then
11: zsi (t
s
i,j)← (1, dsi (tsi,j−1),xi, tsi,j, tsi,j2), rsi (tsi,j)← (1, dsi (tsi,j−1), tsi,j)
12: ysi (t
s
i,j)← Normal(zsi (tsi,j)βl + rsi (tsi,j)bi, σ2l )
13: dsi,j ← Normal((1, ysi (tsi,j),xi)βd, σ2d)
14: j ← j + 1
15: else
16: Jsi ← j − 1, continue ← false
17: esi,T si ← {(tsi,0, dsi,0), . . . , (tsi,Jsi , dsi,Jsi )} and ysi ← (ysi (tsi,1), . . . , ysi (tsi,Jsi ))
18: Compute Ri(T
s
i )
19: end if
20: end while
Next we compute the gradient of the log-likelihood of the MTPP, ∇θ log p(ei,Ti |
yi,xi,φ,θ), using the parametrization defined in (2.3). The details are described in
Supplementary Section D. Lastly, we integrate out φ in computing ∇θGi(θ) using
the Monte Carlo method since it is analytically intractable. Suppose that we have K
MCMC draws from the posterior distribution of φ and we denote the k-th draw as φk,
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then ∇θGi(θ) can be approximated as follows:
∇θGi(θ) ≈
∑K
k=1E(yi,Ti,ei,Ti )∼p(yi,Ti,ei,Ti |θ,φk)[Ri(Ti)∇θ log p(ei,Ti | yi,xi,φk,θ)]
K
.
(3.2)
To compute each term of the summation in the numerator of (3.2), we first sample Ti,
yi, and ei,Ti from p(yi, Ti, ei,Ti | θ,φk) using Algorithm 1 to compute Ri(Ti) for each
φk, then multiply the gradient of the log-probabilities of visitation times and dosages
under the MTPP policy. The entire SGD algorithm for finding the optimal parameter
θ˜i is described in Algorithm 2, where Gi(θi,m) denotes the expected reward in iteration
m. Note that, in the step 7 of Algorithm 2, we subtract the average reward from each
individual reward: this “baseline subtraction” trick significantly reduce the variance
while still yielding an unbiased estimate of the gradient (Williams, 1992; Greensmith
et al., 2004).
Algorithm 2 Stochastic Gradient Descent for optimizing θ for patient i
Input θ0, φk (k = 1, . . . K), xi, yi,0.
Output θ˜i
1: Initialize θi,1 ← θ0
2: for m:=1 to M-1 do
3: for k:=1 to K do
4: do Algorithm 1(θi,m, φk, xi, yi,0) to sample Ri,k, e
s,k
i,T si,k
, and ys,ki .
5: end for
6: Gi(θi,m)←
∑K
k=1Ri,k
K
7: ∇θGi(θi,m)←
∑K
k=1(Ri,k−Gi(θi,m))∇θ logp(es,ki,Ts
i,k
|ys,ki ,xi,φk,θi,m))
K
8: θi,m+1 ← θi,m + si,m∇θGi(θi,m)
9: end for
10: m∗ ← arg maxmGi(θi,m)
11: θ˜i ← θi,m∗
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4 Simulation Study
To demonstrate the advantage of the proposed Bayesian joint model, we compared
it to an alternative model that breaks the connection between longitudinal and survival
processes. Furthermore, to illustrate the benefit of optimizing the personalized clinical
decision, we compared the expected reward under the estimated optimal clinical deci-
sion to alternative strategies of scheduling follow-up visitations on a regular basis, e.g.,
every three months (Israni et al., 2014).
4.1 Simulation setup
We simulated a dataset mimicking the DIVAT dataset composed of longitudinal
creatinine measurements, follow-up schedules, tacrolimus dosages, and survival events
for I = 500 patients. We considered three baseline covariates in xi: donor age (AgeD),
delayed graft function (DGF), and body mass index (BMI). DGF is a binary variable
with 1 indicating that the patient used dialysis within the first week of the trans-
plant, 0 otherwise. For each patient, the donor age and BMI were generated from
Normal(52.5, 15.82) and Normal(24.3, 4.52), respectively, and then standardized. Pa-
tients’ delayed graft functions were generated from Bernoulli(0.4) independently. In
the MTPP model for follow-up schedules, the simulated true parameters were set to be
ν1 = 2.5, ν2 = 1.5, µ = −4.8, ξ = 2, and βα = (9.5,−1.5)T so that a higher creatinine
level results in a higher visitation intensity; for assigning dosages, the simulated true
βd was set to be (1, 0.2, 0.15, 0.2, 0.15)
T and σd = 0.3. In modeling log-transformed
longitudinal creatinine levels, the simulated true parameters were set to be βl =
(5.3, 0.1, 0.3, 0.4, 0.25,−1×10−4, 3×10−8)T , σl = 0.1, and Σb =

0.04 0 0
0 0.0049 0
0 0 10−8
.
Note that the last two terms in the simulated true βl were small since the times were
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recorded in days. Patients’ initial log-transformed creatinine levels right after trans-
plantation yi,0’s were independently generated from Normal(5, 0.1
2). In the survival
submodel (2.6), we assumed that the simulated true parameters were h0 = 5, s = 1.05,
βs1 = 1, βα = −5, βs2 = 0.9, βs3 = −0.75, and ηtox = 50. The censoring times Ci’s were
independently generated from Weibull(3, 8000). Based on the proposed Bayesian joint
model in Section 2, we generated the data yi, ei,T˜i , T˜i, δi for each patient i, i = 1, . . . , I.
The simulated dataset had a total of 14,395 follow-up visitations for 500 patients
with a 10.8% censoring rate. The median survival time was 1,684 days with the shortest
being 24 days and the longest being 10,016 days. Supplementary Figure S1 plots the
simulated longitudinal creatinine levels and follow-up schedules with dosages for four
randomly selected patients.
4.2 Results: model fitting
We applied the proposed Bayesian joint model to the simulated dataset. The hy-
perparameters were set to be βd0 = βl0 = βα0 = 0, Σβd = Σβl = Σβα = 100
2I,
pid1 = pid2 = pil1 = pil2 = pis3 = pis4 = 0.01, pis1 = pis2 = 0.01, βs0 = βv0 = 0,
σ2s0 = σ
2
v0 = 100
2, piv1 = 400, piv2 = 200. We ran 20,000 MCMC iterations with an
initial burn-in of 5,000 iterations and a thinning factor of 50. The convergence was
assessed using R package coda, including traceplots of the post-burn-in MCMC samples
for some randomly selected parameters (Supplementary Figure S2), showing no issues
of non-convergence. We first report on the performance of the proposed joint model
in terms of parameter estimation. Supplementary Figure S3 plots the 95% estimated
credible intervals (CIs) for selected parameters, showing that all 95% CIs are centered
around the simulated true values. As another metric of performance, we computed
the mean squared error (MSE) taken as the averaged squared errors between the post-
burn-in MCMC posterior samples and the simulated true values. Supplementary Table
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S1 summarizes the MSE and the standard deviation of squared errors, indicating that
the proposed joint model can accurately estimate parameters.
As the proposed model represents the first effort in the literature to jointly model
clinical decisions, longitudinal markers, and the survival event, there is no existing
method we can compare with. To demonstrate the advantage of jointly modeling
longitudinal creatinine levels and the survival event, we compared the proposed model
with an alternative “separate longitudinal and survival (SIS)” model that breaks the
connection between the longitudinal and survival submodels by replacing the process
y∗i (t) with the observational data yi(t) in the hazard model (2.6). We first compared
the two models by checking their model adequacy using deviance information criterion
(DIC) (Spiegelhalter et al., 2002): the joint model has a DIC value of 220,412 while the
SLS has a DIC of 220,458, indicating that the proposed joint model fits data slightly
better. Furthermore, we compared the two models in terms of parameter estimation.
Table 1 reports the simulated true values of parameters in the survival submodel, and
posterior means of these parameters under the joint model and the SLS model with
95% CIs, showing that the joint model estimates parameters more accurately.
Truth Joint posterior mean (95% CI) SLS posterior mean (95% CI)
βs1 1 1.1(0.92,1.26) 1.19(0.94,1.6)
βs2 0.9 1.25(0.74,1.95) 1.41(0.63,2.3)
βs3 -0.75 -0.92(-1.62,-0.33) -1.03(-1.8,-0.18)
βα -5 -5.01(-5.51,-4.47) -5.16(-6.14,-4.56)
h0 5 4.36(3.44,5.35) 3.89(1.6,5.22)
s 1.05 1.06(0.99,1.12) 1.06(0.97,1.13)
Table 1: Parameter estimation under the joint and SLS models.
4.3 Results: personalized optimal clinical decision estimation
We applied the proposed policy gradient method in Section 3 to the simulated
dataset to estimate the personalized optimal clinical decision that maximizes one pa-
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tient’s graft median survival time, i.e., Ri = log(T̂i), where T̂i is the median survival
time of patient i. The starting parameter values θ0 in Algorithm 2 were set to be the
estimated posterior means of these parameters from posterior inference, which can be
considered as the estimates of how physicians treated patients in the simulated data.
Therefore, the goal of the optimization procedure is to improve physicians’ current
treatment strategy in terms of prolonging patients’ survival.
We implemented Algorithm 2 with M = 1000 steps to estimate the personalized
optimal parameter θ˜i for two randomly selected patients, denoted as S1 and S2. Patient
S1 had a DGF of 0, donor age of 54.2 years, and BMI of 24, while patient S2 had a DGF
of 1, donor age of 37.4 years, and BMI of 24.8. Figure 4(a, b) plots the expected mean
reward versus SGD iterations. For patient S1, the expected mean reward increases
from an initial value of 7.65 to its maximum in the SGD, 7.69, which corresponds to
a predictive median survival time of 2,209 days, a 4.6% increase from its initial value
2,111. For patient S2, the expected mean reward goes from an initial value of 7.69 to a
maximum at 7.76. This corresponds to the predictive median survival time increasing
from 2,203 days to 2,383 days, an 8.2% improvement.
To further interpret the estimated optimal “policy” parameters for patients S1 and
S2, we compared the initial parameter values of the SGD–posterior means, with the
optimized values by the SGD in Table 2. Recall that the dosage model is di,j =
(1, yi,j,xi)βd + d. Denote βd = (βd1, βd2, . . . , βdL)
T , where L is the dimension of βd.
Since xi denotes the baseline covariate and does not change over time, we define the
personalized dosage intercept to be β˜d = (1,xi)(βd1, βd3, . . . , βdL)
T so that optimizing
βd is equivalent to optimizing (βd2, β˜d). As shown in Table 2, the optimized dosage
parameters β˜d and βd2 for patient S1 were lower than the estimated posterior means,
indicating that patient S1 would benefit from a lower dosage for the same creatinine
level compared to the observed dosages. In contrast, the optimal β˜d and βd2 were
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Figure 4: Panels (a, b) plot the expected mean reward versus SGD iterations for two
randomly selected patients S1 and S2. Panels (c, d) plot the density of the predictive
median survival times under our method and the three alternative strategies for patients
S1 and S2.
higher than the posterior means for patient S2, indicating the preference for higher
dosages. The optimal dosage errors, σ2d, for both patients were significantly lower
than the initial value, indicating that a lower variance in the dosing procedure would
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benefit patient survival. The optimal baseline visitation intensity µ and the peak time
parameter ν1 were both roughly the same as their posterior means, indicating that the
simulated follow-up schedules were close to optimal. However, the visitation intensity
shape parameter ν2 increased from 1.464 to 1.778 and 2.008 for patients S1 and S2
respectively and thus implies a higher intensity around the peak time ν1: intuitively,
the optimized policy learns to be more certain about the “optimal peak time.”
Table 2: Simulation: Stochastic Gradient Descent Optimal Parameter Results
θ˜0 θ˜S1 θ˜S2
β˜d: personalized dosage intercept S1: 0.864, S2:0.987 0.746 1.316
βd2: dosage effect of creatinine 0.200 0.153 0.307
σ2d: dosage error 0.0940 0.0217 0.00252
µ: baseline visitation intensity -4.781 -4.821 -4.785
ν1: visitation intensity peak 2.512 2.416 2.519
ν2: visitation intensity shape 1.464 1.778 2.008
In addition, to illustrate the advantage of optimizing both follow-up schedules and
dosages, we compared our results to alternative strategies based on regular visits. As
studied in Israni et al. (2014), during the first year post-transplant, patients were most
frequently seen every 1 month or 3 months, depending on their physicians. After the
first year, stable patients were most frequently referred back between 4-6 months but
the follow-up frequency was reported to vary from 0-12 months. We considered three
alternative follow-up strategies: recommend patients to follow up every 1 month, 3
months, and 6 months. The dosages at follow-up visitations were still optimized in
the same way as the proposed joint model with the policy gradient method. Figure
4(c, d) show the density plots of 100 realizations of the predictive median survival
times under our method and the three alternative strategies for patients S1 and S2.
Comparing the predictive median survival times under the three regular visitation
strategies, we can see that more frequent visitations yield longer median survival times.
The optimized visitation schedule under the proposed method outperforms the three
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alternative strategies although it yields a similar overall visitation frequency with the
strategy of “regular visits every 3 months” (not shown), highlighting the importance of
optimizing visitation schedules based on longitudinal clinical measurements to prolong
patients’ survival.
5 Application: DIVAT Data Analysis
We extracted data from Nantes University Hospital Centers in the DIVAT cohort
(www.divat.fr), yielding a total of N = 947 patients who received a first or second
renal graft transplanted from a living or heart-beating deceased donor between 2000
and 2014. All patients in the dataset received an initial maintenance therapy with
tacrolimus and did not experience graft failure or death during hospitalization. Imme-
diately after transplantation, several baseline covariates as risk factors for graft failure
were collected: donor age (AgeD), recipient age (AgeR), delayed graft function (DGF)
defined as the indicator of the use of dialysis within the first week of transplant (1=used
dialysis, 0=didn’t use dialysis), diabetes history (Diab) with 1 indicating the patient
has a history of diabetes and 0 otherwise, type of donor (Type), and body mass index
(BMI). There were two types of donors: donation after brain death but with heart beat-
ing (Type=1) and donation by a living donor (Type=0). Table 3 summarizes patients’
characteristics at baseline immediately after transplantation. For each patient, longi-
tudinal data were collected from the date of transplantation until the graft failure or
being censored. At each follow-up visitation, the creatinine level and tacrolimus dosage
were recorded. The next follow-up visitation time was determined by the physician.
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Donor age (years)
Mean ± SD 52.5 ± 15.8
Median 54
Receipient age (years)
Mean ± SD 51.1 ± 14.3
Median 52
Body mass index (BMI)
Mean ± SD 42.3 ± 4.5
Median 23.7
Delayed graft function, n(%)
Yes 329 (34.7%)
No 618 (65.3%)
Diabetes history, n(%)
Yes 140 (14.5%)
No 807 (85.5%)
Type of donor, n(%)
Yes 800 (84.5%)
No 147 (15.5%)
Table 3: Patient characteristics at baseline immediately after transplantation.
5.1 Experimental results: model fitting
We first applied the proposed Bayesian joint model to the DIVAT data with xi =
(AgeDi,AgeRi,DGFi,BMIi,Diabi,Typei). The hyperparameters were set to the same
as in the simulation study. We ran a total of 20,000 MCMC iterations with an initial
burn-in of 5,000 iterations, and a thinning factor of 50. The convergence was assessed
using R package coda and the trace plots for randomly selected parameters were shown
in Supplementary Figure S4, showing no issues of non-convergence.
We plot the estimated posterior means with 95% CIs for some selected parameters
in the dosage, longitudinal, and survival submodels in Figure 5. Figure 5(a) plots pos-
terior means of the linear coefficient βd with respect to the creatinine level and baseline
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covariates in the dosage model. DGF was negatively associated with the dosage, indi-
cating that patients who used dialysis within the first week of transplant were likely to
be assigned lower dosage levels. In contrast, BMI was positively associated with the
dosage since bodyweight-based dosing of tacrolimus is the standard care for patients
after transplantation (Andrews et al., 2017). Diabetes history was positively associated
with the dosage. While the effect of diabetes on tacrolimus was not well characterized
in the literature, Mendonza et al. (2007) showed that the time to maximum concentra-
tion of tacrolimus in the pharmacokinetics study was significantly longer in diabetics
versus nondiabetics. Furthermore, donor type also increased the dosage level, indicat-
ing that patients who received kidney from a non-living donor were more likely to be
assigned higher dosages compared to that from a living donor.
Figure 5(b) plots the estimated posterior means with 95% CIs for the fixed-effects
regression coefficients with respect to the most recent tacrolimus dosage and baseline
covariates in the longitudinal model (2.4). The dosage, donor age, DGF, BMI, and
donor type were positively associated with the creatinine level, which agreed with find-
ings in the literature (Katari et al., 1997; Gerchman et al., 2009; Foucher et al., 2016).
In contrast, the recipient age was negatively associated with the creatinine level, sug-
gesting that younger patients tend to have lower creatinine levels (Maraghi et al., 2016).
Diabetes history also decreased the creatinine level. Hjelmeseth et al. (2010) showed
that a low creatinine was associated with type 2 diabetes in a cross-sectional study.
The estimated posterior means and 95% CIs for selected survival submodel parame-
ters are plotted in Figure 5(c). The posterior mean of the parameter corresponding
to the tacrolimus dosage was positive while that corresponding to the toxicity was
negative, suggesting that a higher tacrolimus drug reduces the hazard but the accu-
mulated toxicity increases the hazard. These results were consistent with findings in
Randhawa et al. (1997) and Bo¨ttiger et al. (1999), who reported nephrotoxicity caused
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Figure 5: Estimated posterior means and 95% CIs for parameters in the dosage, lon-
gitudinal, and survival submodels. The dosages and longitudinal measurements are in
log-scale. The squares represent posterior means.
by long-term high dosages of tacrolimus.
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5.2 Experimental results: personalized optimal clinical deci-
sion estimation
Next, we applied the proposed policy gradient method to estimate the personalized
optimal clinical decision in terms of maximizing a patient’s median survival time. We
initialized the parameters in Algorithm 2 by setting θ0 to be their posterior means.
Algorithm 2 was implemented with M = 1000 steps to estimate θ˜i for two randomly
selected patients, denoted as R1 and R2. Patient R1 at transplantation was 60 years
old with a BMI of 17, no history of diabetes, no DGF, and received donation from a
61-year-old non-living donor. Patient R2 at transplantation was 28 years old with a
BMI of 25.5, no history of diabetes, no DGF, and received a kidney from a living 29-
year-old donor. Patient R1 had an observed survival time of 1,527 days, while patient
R2 had a censored survival time of 4,487 days. Figure 6 plots the predictive median
survival times across SGD iterations for the two patients. Patient R1’s predictive
median survival time increased from 1,793 to 1,895 days at the maximum, a 5.7%
improvement; while patient R2’s predictive median survival time increased from 5,191
to 5,628, an 8.4% gain.
To further interpret the estimated optimal parameters in clinical decisions, we com-
pared their initial values with the optimized values in Table 4. Patient R1’s optimal
dosage parameters, β˜d and βd2, were higher than their posterior means, suggesting that
assgining a higher dosage level compared to what the physician actually did for the
same creatinine level would improve his/her survival outcome. On the other hand, pa-
tient R2’s optimal dosage parameters were both lower than the initial values, so lower
dosage levels are recommended. The optimal dosage errors, σ2d, for both patients were
significantly lower than the initial value, meaning that the optimized policy is more
certain about its dosing decisions so the variance is lower than the observed data. The
optimal baseline visitation intensities µ for both patients were lower than the initial
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Figure 6: The expected mean reward versus SGD iterations for two randomly selected
patients R1 and R2.
value, indicating that they should be instructed to visit less often without the knowl-
edge of their creatinine measurements. Their optimized visitation intensity peak times
were lower than the posterior mean, indicating that they should be scheduled more
frequent follow-ups when their creatinine levels are high. Furthermore, the visitation
intensity shapes were significantly higher than the initial value so the optimized policy
is more certain about the optimal peak time for visitation schedules.
Table 4: DIVAT data: optimal parameters estimated by the policy-optimizing method.
θ˜0 θ˜R1 θ˜R2
β˜d: personalized dosage intercept R1:2.367, R2:2.363 2.788 2.161
βd2: dosage effect of creatinine -0.038 0.076 -0.065
σ2d: dosage error 0.111 0.035 0.0024
µ: baseline visitation intensity -4.197 -4.617 -4.322
ν1: visitation intensity peak 1.479 1.123 1.311
ν2: visitation intensity shape 0.258 0.864 1.261
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5.3 Ablation study: optimizing time or dosage or both
Moreover, to demonstrate the benefit of optimizing the follow-up visitation sched-
ules and dosages together, we compared the predictive median survival times under
the non-optimized initial policy (Non-Opt.) with three versions of optimized policies:
1) only visitation schedules are optimized (Opt.Visits); 2) only dosages are optimized
(Opt.Dosage); and 3) both visitation schedules and dosages are optimized (Opt.Both).
Specifically, Non-Opt. used the parameters estimated from the proposed Bayesian joint
model, mimicking what physicians did as collected in the DIVAT dataset; Opt.Visits
used the optimized parameters from the SGD in the visitation model (2.1) and the
non-optimized parameters in the dosage model (2.2); Opt.Dosage used the optimized
parameters from the SGD in the dosage model and the non-optimized parameters in
the visitation model; Opt.Both is the fully optimized model obtained in section 5.2
which used the optimized parameters in both the visitation and dosage models. Figure
7 plots boxplots for 100 realizations of the predictive median survival times under each
of the four policies. The visitation schedule optimization accounts for more improve-
ment in prolonging the survival for patient R1 compared to patient R2 because, as
shown in Table 4, there was a larger difference between the optimal parameter val-
ues (µ and ν1) in the visitation model and their initial values for patient R1. The
optimized visitation schedule for both patients, as we have discussed in section 5.2,
suggested slightly fewer visits overall, but more frequent visits when their creatinine
levels are high. Comparing Opt.Visits vs. Non-Opt. and Opt.Both vs. Opt.Dosage,
we can see that optimizing treatment schedules is clearly beneficial to these patients,
thus empirically strengthening the motivation of our work. In summary, this analysis
reveals that optimizing both visitation schedules and dosages is necessary to maximize
patients’ survival.
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Figure 7: The boxplots of the predictive median survival times under different policies
of visitation schedules and dosages for patients R1 and R2.
6 Conclusion
In this work, we developed a Bayesian method that jointly models the clinical obser-
vations (e.g, longitudinal measurements and survival time) and clinical decisions (e.g.,
follow-up visitation schedules and dosage assignments). The model components are
connected by sharing certain structures and parameters in order to capture the mutual
influence between the clinical observations and decisions. Moreover, we proposed a
policy gradient method that optimized the personalized clinical decision for better sur-
vival, while parameter uncertainties in the clinical observation model are considered
in the Bayesian framework. Through simulation studies, we demonstrated that the
optimized clinical decision obtained from the proposed approach yields longer predic-
tive median survival times compared to scheduling follow-up visitations on a regular
basis that is commonly used in caring for patients with chronic conditions nowadays.
The analysis of the DIVAT data yields meaningful and interpretable results, showing
that the proposed method has the potential to assist physicians’ decisions on person-
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alized treatment. In addition, we have built an R package doct so that users can apply
the proposed method to datasets in a similar setup that involves longitudinal decision
making and an objective reward to optimize.
There are several potential extensions. Firstly, we consider one longitudinal mea-
surement in the longitudinal process of the joint model. There could be other time-
varying measurements affecting the clinical decision and survival. In our kidney trans-
plantation application, besides creatinine levels, there are other longitudinal measure-
ments recorded such as proteinuria, which represents having protein in the urine and
can be an early sign of kidney disease. The proposed method can be extended to
incorporate other longitudinal measurements by replacing the model in (2.4) with a
multivariate mixed effects model (Chi and Ibrahim, 2006). Secondly, patients may be
heterogeneous, meaning that patients in different subgroups may respond differently
to the treatment or have different disease progression and survival patterns depending
on their clinical characteristics. We can extend the proposed Bayesian joint model to
account for patients’ heterogeneity by adding index i to all parameters in (2.8) and
considering a Bayesian nonparametric prior, such as the Dirichlet process (Ferguson,
1973). Lastly, patients with chronic conditions may take multiple medicines, e.g., my-
cophenolate mofetil (an immunosuppressive drug) and steroids along with tacrolimus
in our kidney transplantation application. Modeling the effects of multiple types of
drugs (and their interactions with clinical observations) and learning their optimal
dosage-assigning policies in the proposed optimization method will be an interesting
and challenging research topic.
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